- Home
- ENTA vs IPHA Comparison
ENTA vs IPHA Comparison
Compare ENTA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- IPHA
- Stock Information
- Founded
- ENTA 1995
- IPHA 1999
- Country
- ENTA United States
- IPHA France
- Employees
- ENTA N/A
- IPHA N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- IPHA Health Care
- Exchange
- ENTA Nasdaq
- IPHA Nasdaq
- Market Cap
- ENTA 154.0M
- IPHA 160.1M
- IPO Year
- ENTA 2013
- IPHA 2019
- Fundamental
- Price
- ENTA $5.10
- IPHA $1.97
- Analyst Decision
- ENTA Buy
- IPHA Strong Buy
- Analyst Count
- ENTA 4
- IPHA 1
- Target Price
- ENTA $17.25
- IPHA $11.50
- AVG Volume (30 Days)
- ENTA 266.6K
- IPHA 28.5K
- Earning Date
- ENTA 05-05-2025
- IPHA 03-27-2025
- Dividend Yield
- ENTA N/A
- IPHA N/A
- EPS Growth
- ENTA N/A
- IPHA N/A
- EPS
- ENTA N/A
- IPHA N/A
- Revenue
- ENTA $66,590,999.00
- IPHA $20,831,349.00
- Revenue This Year
- ENTA N/A
- IPHA $220.44
- Revenue Next Year
- ENTA N/A
- IPHA $81.85
- P/E Ratio
- ENTA N/A
- IPHA N/A
- Revenue Growth
- ENTA N/A
- IPHA N/A
- 52 Week Low
- ENTA $4.09
- IPHA $1.29
- 52 Week High
- ENTA $17.24
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ENTA 43.45
- IPHA 53.30
- Support Level
- ENTA $4.55
- IPHA $1.81
- Resistance Level
- ENTA $5.29
- IPHA $2.00
- Average True Range (ATR)
- ENTA 0.47
- IPHA 0.14
- MACD
- ENTA 0.06
- IPHA 0.02
- Stochastic Oscillator
- ENTA 63.96
- IPHA 53.76
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.